Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI) Tran H; Mehta SR; Eikelboom JWVasc Health Risk Manag 2006[]; 2 (4): 379-87The pathogenesis of ST-elevation myocardial infarction (STEMI) involves plaque disruption, platelet aggregation and intracoronary artery thrombus formation. Aspirin is the cornerstone of antiplatelet therapy in patients with STEMI, reducing the risk of recurrent myocardial infarction or death during the acute phase and long term by about one-quarter. Recent large randomized trials have demonstrated that the addition of clopidogrel to aspirin reduces the risk of major ischemic events by up to a further one-third in patients with STEMI treated with fibrinolytic therapy and undergoing percutaneous coronary intervention, with no significant increase in bleeding. Thus, dual antiplatelet therapy with the combination of clopidogrel and aspirin is becoming the new standard of care for the management of patients with STEMI.|Angioplasty, Balloon, Coronary/adverse effects[MESH]|Aspirin/*therapeutic use[MESH]|Blood Platelets/drug effects[MESH]|Cardiovascular Diseases/etiology/prevention & control[MESH]|Clopidogrel[MESH]|Coronary Artery Bypass/adverse effects[MESH]|Drug Resistance[MESH]|Drug Therapy, Combination[MESH]|Humans[MESH]|Myocardial Infarction/blood/*drug therapy/therapy[MESH]|Platelet Aggregation Inhibitors/pharmacology/*therapeutic use[MESH]|Practice Guidelines as Topic[MESH]|Ticlopidine/*analogs & derivatives/pharmacology/therapeutic use[MESH]|Treatment Outcome[MESH] |
